Therapeutic Insights
Filter News
Found 177 articles
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
-
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
AI gives you a chance to prevent Alzheimer's Dementia
1/8/2021
AI brain mapping with EEG discovered Alzheimer's brainwave and could detect preclinical Alzheimer's dementia(AD). This has been enabled by an innovative AI technology of iMediSync in brain mapping. iMediSync, a biotech startup launched EEG digital biomarker for early detection of Alzheimer's de
-
Pacylex Pharmaceuticals Announces Publication in Breast Cancer Research and Treatment of a New Target for Therapeutic Intervention in Breast Cancer and Preclinical Results of a First-in-Class Therapy
1/7/2021
Edmonton, Alberta--(Newsfile Corp. - January 6, 2021) - Pacylex Pharmaceuticals, an oncology company unlocking a new approach to cancer therapy, today announced the publication in the journal Breast Cancer Research and Treatment data showing treatment with an N-myristoyltransferase (NMT) inhibitor reduces viability of cultured breast cancer cells and inhibits tumor growth in a mouse xenograft mouse model of human breast cancer.
-
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”Virtual Bio-Partnering Platform Connects Biotech Leaders with Investors; Partners
1/7/2021
Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will participate in BIO’s one-on-one virtual partnering meeting during the 39 th annual J.P. Morgan Healthcare Conference taking place January 11 – 14, 2021. The BIO One-on-One Partnering @ JPM platform enables partners and investors to schedule virtual video meetings with Intrommune executives. To
-
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
-
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
1/4/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the e
-
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
12/31/2020
ACCORD is the second pivotal trial of AXS-05 in Alzheimer’s disease agitation No treatments are currently approved for Alzheimer’s disease agitation
-
Cognoptix Announces Formation of a New Board of Directors
12/30/2020
Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. S
-
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
12/29/2020
The data are published in the Proceedings of the National Academy of Sciences Results suggest a potential therapeutic benefit for dapansutrile in patients with neuroinflammatory diseases, e.g., Alzheimer’s Disease
-
Soterix Medical Announces Expanded Clinical Trials for Alzheimer's disease and Mild Cognitive Impairment
12/24/2020
Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer's disease and Mild Cognitive Impairment. Adults over age 65 represent the fastest growing population in the US. Dec
-
It has been said that late-stage clinical trials are where Alzheimer’s drugs go to die—there have been well over 130 failed clinical trials for Alzheimer’s in the last decade. Still, AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to...